Brief: Ryvu Therapeutics Says RVU120 To Be Tested In Phase I Study Run By IPCZD
09/09/2025 10:43
Sept 9 (Reuters) - Ryvu Therapeutics SA RVU.WA: RVU120 TO BE TESTED IN PHASE I STUDY FOR PEDIATRIC MEDULLOBLASTOMA RUN BY IPCZD IPCZD TO RUN "MEDWAY" PROJECT UNDER MEDWAY PROJET 2 MILLION PLN TO BE ALLOCATED FOR RVU120 PRODUCTION FIRST DELIVERY OF RVU120 PLANNED FOR Q2 2026 Source text: ID:nEM3W2cmda Further company coverage: RVU.WA (Reporting by Gdańsk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Q1 Net Loss 12.6 Million Zlotys
Brief: Ryvu Therapeutics Updates Romacyclib Development Strategy
Brief: Ryvu Therapeutics FY Net Loss At 101.2 Mln Zlotys
Brief: Ryvu Therapeutics Extends Research Collaboration And Exclusive License Agreement With BioNTech Until Nov 29, 2028
Brief: Ryvu Therapeutics Signs Grant Agreement With Poland's NCBR For PERO Project